Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA
Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from concept to potential commercialization. LP-003 is the first innovative drug independently...
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
SHANGHAI, April 9, 2026 /PRNewswire/ -- DualityBio ("DualityBio" or the "Company", Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan...